Although we could not perform mutational analysis in the entire tumor specimens, our results suggest that TP53 mutation may have occurred after FGFR3 mutation in the process of bladder recurrence or progression but maintained a favorable molecular biology even with the accumulation of gene mutations. This evidence concerns the gene TP53 and neoplasm.